Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ningetinib

Small molecule · Inhibitor of c-MET (hepatocyte growth factor receptor) (MET), VEGFR2 (KDR) (KDR) and Axl receptor tyrosine kinase (AXL) · developed by Sunshine Lake Pharma Co.

Phase 2 Most advanced trial (none active)
SBFM Developer
1 Registered trials

What is Ningetinib?

Ningetinib is an orally available small-molecule inhibitor of the receptor tyrosine kinases c-MET, VEGFR2, Axl, Mer and Flt3, binding these kinases and blocking their signaling. It is being studied in advanced non-small cell lung cancer (NSCLC).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CT053PTSA
Drug type
Small molecule
Targets
c-MET (hepatocyte growth factor receptor) (MET), VEGFR2 (KDR) (KDR), Axl receptor tyrosine kinase (AXL), Mer receptor tyrosine kinase (MERTK), Flt3 (CD135) (FLT3)
Mechanism
Inhibitor of c-MET (hepatocyte growth factor receptor) (MET), VEGFR2 (KDR) (KDR) and Axl receptor tyrosine kinase (AXL)
Pathways
angiogenesis, tumor cell proliferation, survival, invasion and metastasis signaling
Therapy area
Oncology
Developer
Sunshine Lake Pharma Co., Ltd. (SBFM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
PW3Q92Z6A4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04992858 Phase 2 Advanced NSCLC Withdrawn SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced NSCLC

Other drugs acting on MET / KDR / AXL / MERTK / FLT3

More from Sunshine Lake Pharma Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.

Follow SBFM, the company behind Ningetinib

See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SBFM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.